Multiple endocrine neoplasia type 1 (MEN1)
MEN1 · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Autosomal dominant tumour syndrome (MEN1 gene) predisposing to parathyroid, pancreatic/duodenal neuroendocrine and anterior pituitary tumours. Lifelong biochemical and imaging surveillance detects tumours early.
Red flags
- Severe hypercalcaemia
- Refractory peptic ulceration/diarrhoea (gastrinoma)
- Recurrent hypoglycaemia (insulinoma)
- Visual field loss (pituitary macroadenoma)
- Rapidly growing pancreatic/thymic mass
Assessment
Differential diagnosis
- Sporadic primary hyperparathyroidism
- MEN2
- MEN4
- Sporadic pituitary adenoma
- Sporadic pancreatic neuroendocrine tumour
- Hyperparathyroidism-jaw tumour syndrome
Investigations
- Calcium and PTH (primary hyperparathyroidism)
- Fasting gut hormones, gastrin, glucose/insulin and chromogranin A
- Prolactin, IGF-1 and pituitary function
- Pancreatic/pituitary MRI and functional imaging (DOTATATE)
- Germline MEN1 genetic testing and family cascade
Management
- Suspect MEN1 with the triad of parathyroid, pancreatic and pituitary tumours or a suggestive family history
- Confirm with germline genetic testing and offer cascade testing to relatives
- Enrol gene carriers in lifelong periodic biochemical and imaging surveillance
- Manage primary hyperparathyroidism (usually multigland) with subtotal/total parathyroidectomy
- Control functioning pancreatic tumours: proton pump inhibitors for gastrinoma, surgery for insulinoma
- Treat pituitary tumours per type (dopamine agonist for prolactinoma, etc.)
- Watch for malignant potential of pancreatic/thymic neuroendocrine tumours
- Avoid thymic carcinoid risk awareness (especially male smokers)
- Coordinate multidisciplinary surgical and oncological care
- Provide genetic counselling and psychological support
Drugs & doses
Proton pump inhibitor (e.g. high-dose omeprazole) for gastrinoma acid control
Cabergoline for prolactinoma
Somatostatin analogues (octreotide/lanreotide) for neuroendocrine tumours
Cinacalcet if hyperparathyroidism surgery deferred/unsuccessful
Disposition
Lifelong management in a specialist endocrine/neuroendocrine centre with multidisciplinary surgery and genetics-led family screening.
Complications & pitfalls
- Metastatic pancreatic/duodenal neuroendocrine tumours
- Zollinger-Ellison syndrome complications
- Thymic carcinoid (aggressive)
- Recurrent hyperparathyroidism after surgery
- Pituitary mass effects
Exam pearls
- Hyperparathyroidism is usually the earliest and commonest manifestation and is multigland
- Pancreatic neuroendocrine tumours are the leading cause of MEN1-related death; surveillance is vital
- Gastrinomas are frequently multiple and located in the duodenum
- Cascade genetic testing allows pre-symptomatic surveillance of relatives
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.